JRCT ID: jRCT2080225168
Registered date:20/04/2020
Basic Information
Recruitment status | completed |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 17/04/2020 |
Target sample size | 400 |
Countries of recruitment | Japan,Asia except Japan,North America,Europe,Oceania |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : Selpercatinib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : Pembrolizumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Generic name etc : INN of investigational material : Pemetrexed Therapeutic category code : 422 Antimetabolic agents Dosage and Administration for Investigational material : Generic name etc : INN of investigational material : Cisplatin Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Generic name etc : INN of investigational material : Carboplatin Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : |
Outcome(s)
Primary Outcome | efficacy |
---|---|
Secondary Outcome | efficacy |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | Eli Lilly Japan K.K. |
---|---|
Secondary Sponsor | - |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT04194944,JapicCTI-205264 |